Last reviewed · How we verify

Placebo Inhalation Powder NDPI

GlaxoSmithKline · Phase 3 active Small molecule

Placebo Inhalation Powder NDPI is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Control arm in phase 3 clinical trials (non-therapeutic use). Also known as: ACCUHALER and DISKUS are registered trade marks of the GlaxoSmithKline Group of companies.

Placebo has no active pharmacological mechanism and produces no therapeutic effect beyond the placebo response.

Placebo has no active pharmacological mechanism and produces no therapeutic effect beyond the placebo response. Used for Control arm in phase 3 clinical trials (non-therapeutic use).

At a glance

Generic namePlacebo Inhalation Powder NDPI
Also known asACCUHALER and DISKUS are registered trade marks of the GlaxoSmithKline Group of companies
SponsorGlaxoSmithKline
ModalitySmall molecule
PhasePhase 3

Mechanism of action

Placebo is an inert substance used as a control in clinical trials to measure the effect of expectation and natural disease progression independent of active drug treatment. It serves as a comparator to establish the true efficacy of investigational therapies by isolating the pharmacological effect from psychological and contextual factors.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo Inhalation Powder NDPI

What is Placebo Inhalation Powder NDPI?

Placebo Inhalation Powder NDPI is a Small molecule drug developed by GlaxoSmithKline, indicated for Control arm in phase 3 clinical trials (non-therapeutic use).

How does Placebo Inhalation Powder NDPI work?

Placebo has no active pharmacological mechanism and produces no therapeutic effect beyond the placebo response.

What is Placebo Inhalation Powder NDPI used for?

Placebo Inhalation Powder NDPI is indicated for Control arm in phase 3 clinical trials (non-therapeutic use).

Who makes Placebo Inhalation Powder NDPI?

Placebo Inhalation Powder NDPI is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is Placebo Inhalation Powder NDPI also known as anything else?

Placebo Inhalation Powder NDPI is also known as ACCUHALER and DISKUS are registered trade marks of the GlaxoSmithKline Group of companies.

What development phase is Placebo Inhalation Powder NDPI in?

Placebo Inhalation Powder NDPI is in Phase 3.

Related